Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 151 AL 165

Synthesis, Molecular Modeling, and Evaluation of Novel Sulfonylhydrazones as Acetylcholinesterase Inhibitors for Alzheimer's Disease

Fernandes TB, Cunha MR, Sakata RP, Candido TM, Baby AR, Tavares MT, Barbosa EG, Almeida WP, Parise-Filho R.

Arch Pharm (Weinheim). 2017 Nov;350(11). doi: 10.1002/ardp.201700163. Epub 2017 Sep 22.

The role of the immune system in Alzheimer disease: Etiology and treatment

Jevtic S, Sengar AS, Salter MW, McLaurin J.

Ageing Res Rev. 2017 Nov;40:84-94. doi: 10.1016/j.arr.2017.08.005. Epub 2017 Sep 21.

The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review

Anand A, Patience AA, Sharma N, Khurana N.

Eur J Pharmacol. 2017 Nov 15;815:364-375. doi: 10.1016/j.ejphar.2017.09.043. Epub 2017 Oct 1.

Research advances in the treatment of Alzheimer's disease with polysaccharides from traditional Chinese medicine

Liu Q, Wang SC, Ding K.

Chin J Nat Med. 2017 Sep;15(9):641-652. doi: 10.1016/S1875-5364(17)30093-6.

Genetic and Pharmacological Discovery for Alzheimer's Disease Using Caenorhabditis elegans

Griffin EF, Caldwell KA, Caldwell GA.

ACS Chem Neurosci. 2017 Dec 20;8(12):2596-2606. doi: 10.1021/acschemneuro.7b00361. Epub 2017 Oct 25.

Can small molecule inhibitors of glutaminyl cyclase be used as a therapeutic for Alzheimer's disease?

Wu H.

Future Med Chem. 2017 Nov;9(17):1979-1981. doi: 10.4155/fmc-2017-0190. Epub 2017 Oct 27.

24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial

Soininen H, Solomon A, Visser PJ, Hendrix SB, Blennow K, Kivipelto M, Hartmann T; LipiDiDiet clinical study group.

Lancet Neurol. 2017 Dec;16(12):965-975. doi: 10.1016/S1474-4422(17)30332-0. Epub 2017 Oct 30.

Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer's Disease

Ouyang QQ, Zhao S, Li SD, Song C.

Mar Drugs. 2017 Nov 7;15(11):322. doi: 10.3390/md15110322.

Editorial: Multi-target Drug Discovery - Part I

Chen JN.

Curr Top Med Chem. 2017;17(27):2997-2999. doi: 10.2174/156802661727171102165810.

Alzheimer's Disease-Related Dementias Summit 2016: National research priorities

Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA, Carmichael ST, Dickinson SL, Dickson DW, Emr M, Fillit H, Greenberg SM, Hutton ML, Knopman DS, Manly JJ, Marder KS, Moy CS, Phelps CH, Scott PA, Seeley WW, Sieber BA, Silverberg NB, Sutherland ML, Taylor A, Torborg CL, Waddy SP, Gubitz AK, Holtzman DM.

Neurology. 2017 Dec 5;89(23):2381-2391. doi: 10.1212/WNL.0000000000004717. Epub 2017 Nov 8.

A benzothiazole/piperazine derivative with acetylcholinesterase inhibitory activity: Improvement in streptozotocin-induced cognitive deficits in rats

Demir Özkay Ü, Can ÖD, Sağlık BN, Turan N.

Pharmacol Rep. 2017 Dec;69(6):1349-1356. doi: 10.1016/j.pharep.2017.06.009. Epub 2017 Jun 30.

Novel Treatment Strategies Using TiO(2)-Nanowired Delivery of Histaminergic Drugs and Antibodies to Tau With Cerebrolysin for Superior Neuroprotection in the Pathophysiology of Alzheimer's Disease

Sharma A, Menon PK, Patnaik R, Muresanu DF, Lafuente JV, Tian ZR, Ozkizilcik A, Castellani RJ, Mössler H, Sharma HS.

Int Rev Neurobiol. 2017;137:123-165. doi: 10.1016/bs.irn.2017.09.002. Epub 2017 Nov 6.

Role of Vitamin E in the Treatment of Alzheimer's Disease: Evidence from Animal Models

Gugliandolo A, Bramanti P, Mazzon E.

Int J Mol Sci. 2017 Nov 23;18(12):2504. doi: 10.3390/ijms18122504.

Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease

Alam J, Blackburn K, Patrick D.

J Prev Alzheimers Dis. 2017;4(4):273-278. doi: 10.14283/jpad.2017.41.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias